title: Alzheimer's disease and age-related memory decline (preclinical).
abstract: An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer's disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as "Mild Cognitive Impairment" (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD and MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy and adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.
authors.affiliation: Department of Pharmacology and Toxicology and Small Animal Behavior Core, Medical College of Georgia, Augusta, GA 30912, USA. aterry@georgiahealth.edu
authors.forename: Alvin V
authors.initials: AV
authors.lastname: Terry
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Callahan
authors.forename: Brandon
authors.initials: B
authors.lastname: Hall
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Webster
mesh_terms: D000375:Aging / Q000502:physiology / Q000523:psychology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004195:Disease Models, Animal; D054828:Histamine H3 Antagonists / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D008559:Memantine / Q000627:therapeutic use; D008569:Memory Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D018697:Nootropic Agents / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D057170:Translational Research, Biomedical
chemical_list: D002800:Cholinesterase Inhibitors; D054828:Histamine H3 Antagonists; D008024:Ligands; D018697:Nootropic Agents; D010726:Phosphodiesterase Inhibitors; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D011985:Receptors, Serotonin; D008559:Memantine